Clinical Implication of Multi-Parameter Flow Cytometry in Myelodysplastic Syndromes

Duetz, Carolien; Westers, Theresia M.; Loosdrecht, Arjan A. van de

doi:10.1159/000490727

Cited by 26 publications

(34 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar to the results reported by Della Porta et al, in this real‐life setting, we found a sensitivity of 70.1%, specificity 91.2%, PPV of 94.2%, NPV of 62.1%, and LHR+ of 7.9 in low/Int‐1 IPSS patients, showing how robust this score is. It was noted that the score tended to be better in Int‐2/high IPSS patients, with a sensitivity of 96.5% and a LHR+ of 11, suggesting that, as previously reported, BM dysplasia detected by FC increases with disease progression . The higher “Ogata score” in high‐risk patients was mainly due to an increase in myeloid progenitor cells and a decreased in B‐cell progenitor compartments.…”

Section: Discussionsupporting

confidence: 61%

“…4,9,[21][22][23][24][25][26][27] In this study, we report the results of the diagnostic utility of the and a LHR+ of 11, suggesting that, as previously reported, BM dysplasia detected by FC increases with disease progression. 5,28 The higher "Ogata score" in high-risk patients was mainly due to an increase in myeloid progenitor cells and a decreased in B-cell progenitor compartments. Similar results were found using the revised IPSS score ( Focusing our analysis on patients who are very difficult to diagnose in clinical practice like those without specific markers of dysplasia (such as patients without ring sideroblasts, excess of blasts, or chromosomal abnormalities), the diagnostic power of this score is lower than in whole population (sensitivity is 67%, specificity of 91%, and LHR+ 7.6), but is similar to data previously reported by Della Porta et al 9 Hypoplastic or hypocellular MDS is another interesting population, which represent around 10%-15% of total MDS patients.…”

Section: Discussionmentioning

confidence: 99%

“…Current recommendations for MDS diagnosis support the use of FC as a valuable additional diagnostic tool . Several FC scoring systems have been published to provide useful information for MDS diagnosis, having good sensitivity and specificity to discriminate MDS from other cytopenias . Currently, many different FC scoring systems are available, containing a wide variability in terms of numbers and combination of markers used, the amount of parameters analyzed, and the weight assigned to each parameter .…”

Section: Introductionmentioning

confidence: 99%

“…2,3 Several FC scoring systems have been published to provide useful information for MDS diagnosis, having good sensitivity and specificity to discriminate MDS from other cytopenias. 4,5 Currently, many different FC scoring systems are available, containing a wide variability in terms of numbers and combination of markers used, the amount of parameters analyzed, and the weight assigned to each parameter. 3,5,6 European Leukemia Net Working Group for FC in MDS (IMDSFlow) recommend the Ogata scoring system for screening purposes.…”

Section: Introductionmentioning

confidence: 99%

“…4,5 Currently, many different FC scoring systems are available, containing a wide variability in terms of numbers and combination of markers used, the amount of parameters analyzed, and the weight assigned to each parameter. 3,5,6 European Leukemia Net Working Group for FC in MDS (IMDSFlow) recommend the Ogata scoring system for screening purposes. 7 This score includes four parameters: percentage of CD34+ myeloid progenitor cells among total nucleated cells; percentage of B-cell progenitors within the CD34+ subset; CD45 expression on myeloid progenitors compared to its expression on lymphocytes; and side scatter (SSC) of granulocytes compared to SSC on lymphocytes.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Flow cytometry “Ogata score” for the diagnosis of myelodysplastic syndromes in a real‐life setting. A Latin American experience

Montauban

Hernandez‐Perez

Velloso

et al. 2019

Int J Lab Hematology

View full text Add to dashboard Cite

Introduction Flow cytometry (FC) is a helpful tool for the diagnosis of myelodysplastic syndrome (MDS). Different FC score systems have been developed. The “Ogata score” is a simple diagnostic score that has been validated having a sensitivity of 69% and a specificity of 92% in low‐risk MDS. We aimed to study the feasibility and the utility of the “Ogata score” for the diagnosis of MDS among Latin America (LA) Laboratories. Methods This is a case and control study conducted in LA institutions members of Grupo Latinoamericano de Mielodisplasia (GLAM). A total of 146 MDS patients and 57 control patients were included. “Ogata score” was calculated. Results The sensitivity of “Ogata score” was 75.6% (95% CI, 66.8‐81.3), specificity was 91.2% (95% CI, 79.7‐96.7), PPV was 95.6% (95% CI, 88.5‐98.3), and NPV was 65.4% (95% CI, 49.1‐71.9). In low/intermediate‐1 IPSS patients group, the sensitivity was 70.1% (95% CI, 60.2‐78.2), specificity was 91.2% (CI‐95%, 79.7‐96.7), PPV was 94.2% (95% CI, 86.4‐97.8), and NPV was 62.1% (95% CI, 53.0‐78.7). In the group of patients “without MDS specific markers” (patients without ring sideroblasts, blast excess, or chromosomal abnormalities), the sensitivity was 66.7% (CI‐95%, 55.8‐76.0), specificity was 91.2% (95% CI, 79.7‐96.7), PPV was 92.3% (95% CI, 82.2‐97.1), and NPV was 63.5% (95% CI, 51.9‐73.5). Conclusions The diagnostic power found in this study was similar to the reported by Della‐Porta et al. Also in LA, the analysis was made in modern equipment with acquisition of at least 100 000 events which permits a good reproducibility of the results.

show abstract

Section: Discussionsupporting

confidence: 61%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Flow cytometry “Ogata score” for the diagnosis of myelodysplastic syndromes in a real‐life setting. A Latin American experience

Montauban

Hernandez‐Perez

Velloso

et al. 2019

Int J Lab Hematology

View full text Add to dashboard Cite

show abstract

Myelodysplastic Syndromes

Borate¹

2022

Holland‐Frei Cancer Medicine

View full text Add to dashboard Cite

Overview Primary, secondary, and familial myelodysplastic syndromes (MDS) became a reportable group of malignancies in 2001. Over the past 20 years, there have been tremendous strides in genetic and translational research, which has influenced the pathological diagnosis and classification, risk stratification scoring systems, and genomic characterization of MDS. In certain cases, this has led to more personalized therapy options such as Luspatercept in RARS patients with SF3B1 mutations. In this chapter, we discuss the history behind the various MDS prognostic risk stratification and classifications. We also examine our current understanding of MDS pathophysiology, the complexities with establishing an MDS diagnosis including the evolving diagnostic criteria, and the use of next‐generation sequencing analyses. Then, we outline both the standard of care therapeutic options including hypomethylating agents, and their impact over the past decade, as well as multiple clinical trials and treatment options being investigated for MDS patients. Finally, we discuss what personalized treatments and possible preventative strategies we may expect to see – in the next decade – for MDS development in high‐risk patient populations.

show abstract

Computational flow cytometry as a diagnostic tool in suspected‐myelodysplastic syndromes

et al. 2021

Self Cite

View full text Add to dashboard Cite

The diagnostic work‐up of patients suspected for myelodysplastic syndromes is challenging and mainly relies on bone marrow morphology and cytogenetics. In this study, we developed and prospectively validated a fully computational tool for flow cytometry diagnostics in suspected‐MDS. The computational diagnostic workflow consists of methods for pre‐processing flow cytometry data, followed by a cell population detection method (FlowSOM) and a machine learning classifier (Random Forest). Based on a six tubes FC panel, the workflow obtained a 90% sensitivity and 93% specificity in an independent validation cohort. For practical advantages (e.g., reduced processing time and costs), a second computational diagnostic workflow was trained, solely based on the best performing single tube of the training cohort. This workflow obtained 97% sensitivity and 95% specificity in the prospective validation cohort. Both workflows outperformed the conventional, expert analyzed flow cytometry scores for diagnosis with respect to accuracy, objectivity and time investment (less than 2 min per patient).

show abstract

Clinical Implication of Multi-Parameter Flow Cytometry in Myelodysplastic Syndromes

Cited by 26 publications

References 60 publications

Flow cytometry “Ogata score” for the diagnosis of myelodysplastic syndromes in a real‐life setting. A Latin American experience

Flow cytometry “Ogata score” for the diagnosis of myelodysplastic syndromes in a real‐life setting. A Latin American experience

Myelodysplastic Syndromes

Computational flow cytometry as a diagnostic tool in suspected‐myelodysplastic syndromes

Contact Info

Product

Resources

About